NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.105
+0.005 (5.00%)
Mar 10, 2026, 9:59 AM AEST

ASX:NSB Ratios and Metrics

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2020 - 2016
Market Capitalization
33296112648
Upgrade
Market Cap Growth
521.59%400.23%-49.60%-55.56%-46.27%222.72%
Upgrade
Enterprise Value
2724281643
Upgrade
Last Close Price
0.100.090.040.080.180.34
Upgrade
PE Ratio
--17.84---
Upgrade
PS Ratio
104.61-2.622.32-50.13
Upgrade
PB Ratio
2.021.721.082.444.683.29
Upgrade
P/TBV Ratio
5.223.991.172.604.973.38
Upgrade
P/FCF Ratio
--136.31---
Upgrade
P/OCF Ratio
--130.72---
Upgrade
EV/Sales Ratio
84.62-1.111.65-44.93
Upgrade
EV/EBITDA Ratio
--9.93---
Upgrade
EV/EBIT Ratio
--15.76---
Upgrade
EV/FCF Ratio
--57.68---
Upgrade
Net Debt / Equity Ratio
-0.39-0.43-0.93-1.05-1.31-0.97
Upgrade
Net Debt / EBITDA Ratio
2.363.79-20.094.410.694.42
Upgrade
Net Debt / FCF Ratio
4.587.72-116.752.131.045.38
Upgrade
Asset Turnover
0.03-0.410.76-0.10
Upgrade
Quick Ratio
31.1449.3558.468.303.3163.61
Upgrade
Current Ratio
31.6249.5658.878.393.3464.58
Upgrade
Return on Equity (ROE)
-29.65%-16.65%6.46%-20.93%-103.71%-34.82%
Upgrade
Return on Assets (ROA)
-19.42%-11.21%1.81%-11.24%-58.19%-21.98%
Upgrade
Return on Capital Employed (ROCE)
-20.50%-11.90%2.90%-25.00%-190.30%-22.40%
Upgrade
Earnings Yield
-9.55%-6.38%5.61%-9.31%-40.41%-6.61%
Upgrade
FCF Yield
--3.25%0.73%-20.08%-26.90%-5.47%
Upgrade
Buyback Yield / Dilution
-64.61%-1.49%-0.72%---83.04%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.